Reconciliation to group net income

Reconciliation


  2010 2009
€ in millions Other financial result Net income Other financial result Net income
1 Net income attributable to Fresenius SE & Co. KGaA adjusted for the special items relating to the acquisition of APP Pharmaceuticals.
2 The special items are included in the column "Corporate/Other" in the segment reporting.
3 Net income attributable to Fresenius SE & Co. KGaA
Net income1   660   514
Other financial result:2        
Mandatory Exchangeable Bonds (MEB) (mark-to-market accounting) -98 -70 -37 -26
Contingent Value Rights (CVR) (mark-to-market accounting) 32 32 6 6
Earnings according to U.S. GAAP3 -66 622 -31 494

  2010 2009
€ in millions Other financial result Net income Other financial result Net income
1 Net income attributable to Fresenius SE & Co. KGaA adjusted for the special items relating to the acquisition of APP Pharmaceuticals.
2 The special items are included in the column "Corporate/Other" in the segment reporting.
3 Net income attributable to Fresenius SE & Co. KGaA
Net income1   660   514
Other financial result:2        
Mandatory Exchangeable Bonds (MEB) (mark-to-market accounting) -98 -70 -37 -26
Contingent Value Rights (CVR) (mark-to-market accounting) 32 32 6 6
Earnings according to U.S. GAAP3 -66 622 -31 494

The table above shows the special items relating to the acquisition of APP Pharmaceuticals in the reconciliation from net income1 to earnings according to U.S. GAAP.

The Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) are recognized as liabilities. The repayment value of the CVR and the derivative elements of the MEB are measured at market prices. The change in value (mark-to-market accounting) results either in a gain or an expense until the end of maturity.

Since Adjusted EBITDA for the CVR measuring period did not exceed the threshold amount, no amounts will be payable on the CVRs and the CVRs will expire valueless.

QUICKFINDER

History

Tools